drugset / Trial / NCT02936154

Study for MR Formulation of PF-06650833 in Healthy Adult Japanese Subjects

NCT02936154

Phase 1 Completed 10 enrolled Pfizer
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this study is to evaluate the tolerability, safety and pharmacokinetics of PF-06650833 orally administered as modified release tablets in healthy Japanese subjects.

Timeline

Start
2016-08
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ZIMLOVISERTIB Small molecule 300 mg Oral

Indications

No indication recorded.